Bionomics Limited, a drug development company in Adelaide, Australia, says the French national medical agency and ethics committee for Strasburg Hospital have approved the company’s request to conduct clinical trials for BNC210, Bionomics’ treatment of anxiety and depression now in development.
The first clinical study will examine whether BNC210 reduces panic and anxiety symptoms induced by pharmacological means in healthy volunteers. The company says it will use the peptide CCK-4 to induce symptoms of panic and anxiety. Bionomics has previously reported that BNC210, in a rodent model of CCK induced anxiety, overcomes the effects of CCK.
The second trial, says Bionomics, will evaluate BNC210’s effects on the brain using electro-encephalograph and quantitative assessments of memory function. In this trial the effects of BNC210 will be compared with Lorazepam, a drug closely related to Valium, which is known to have the adverse side effect of causing memory impairment.
Bionomics’ subsidiary, Neurofit SAS, is the designated sponsor of the trials. Both trials will be conducted in parallel in France by Forenap Pharma, a contract research organization. Data from the trials are expected to be available in the first quarter of 2011.
You must be logged in to post a comment.